Immunovant, Inc.
IMVT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,799,139 | $2,733,968 | $2,590,400 | $3,639,258 |
| - Cash | $521,870 | $598,912 | $713,971 | $374,685 |
| + Debt | $0 | $0 | $98 | $23 |
| Enterprise Value | $2,277,269 | $2,135,056 | $1,876,527 | $3,264,596 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$131,657 | -$127,117 | -$113,716 | -$114,203 |
| % Margin | – | – | – | – |
| Net Income | -$126,502 | -$120,613 | -$106,449 | -$111,122 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.73 | -0.71 | -0.64 | -0.76 |
| % Growth | -2.8% | -10.9% | 15.8% | – |
| Operating Cash Flow | -$102,515 | -$117,411 | -$110,637 | -$100,391 |
| Capital Expenditures | $0 | $0 | -$201 | -$180 |
| Free Cash Flow | -$102,515 | -$117,411 | -$110,838 | -$100,571 |